Suppr超能文献

[舒更葡糖钠用于胸腔镜下肺癌根治术患者拮抗神经肌肉阻滞的分析]

[Analysis of sugammadex for antagonistic neuromuscular block in patients with radical resection of lung cancer under thoracoscope].

作者信息

Ba Y F, Liu Y N, He S H, Li H M, Wang H R, Zhu J P, Xing W Q, Li C S

机构信息

Department of Thoracic Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450003, China.

Medical Department, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450003,China.

出版信息

Zhonghua Yi Xue Za Zhi. 2020 Jan 21;100(3):213-219. doi: 10.3760/cma.j.issn.0376-2491.2020.03.011.

Abstract

To investigate the efficacy and safety of sugammadex for antagonistic neuromuscular block in patients with radical resection of lung cancer under thoracoscope. One hundred patients undergoing radical resection of lung cancer under thoracoscope in Affiliated Cancer Hospital of Zhengzhou University from March to September in 2019, were randomly divided into control group (group C) and sugammadex group (group S). All patients were anaesthetized (induced and maintained) with intravenous target-controlled infusion of propofol and remifentanil, and intermittent intravenous injection of the neuromuscular block of rocuronium. During the operation, the bispectral index (BIS) was used to monitor the depth of anesthesia, and the neuromuscular block was assessed with TOF. Single-lung mechanical ventilation and double-lumen endotracheal intubation were carried out, and patient-controlled analgesia after operation were enforced. Patients in group C received neostigmine (2 mg) combined with atropine (0.5-1.0 mg) after thoracic closure, while patients in group S received sugammadex (2 mg/kg) at TOF count (≥2) after thoracic closure, and then double-lumen endotracheal tubes were extubated according to extubation indications. At these time points: T(0) (immediate before anesthesia induction), T(1) (immediate before tracheal intubation), T(2) (immediately after thoracic closure), T(3) (1 h after operation), T(4) (6 h after operation), T(5) (24 h after operation), T(6)(48 h after operation), the heart rate(HR) and mean arterial pressure (MAP) were recorded, QT interval (V3 ECG) were measured and calculated, indicators of liver function [alanine transaminase (ALT), aspartate transaminase(AST)], renal function [blood urea nitrogen (BUN), creatinine (Cre)] and clotting function [thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen (FIB)] were detected. The duration of operation, postoperative conditions within 48 hours after operation(the time of tracheal tube extubation, respiratory suppression/dysfunction, allergy, nausea and vomiting, itching of skin, abnormal sensation), pathological types and the postoperative hospital stay were recorded. There were no significant differences of the age, sex ratio, body mass index (BMI), American Society of Anesthesiologists (ASA) grading ratio, duration of operation, pathological types and the postoperative hospital stay, HR, MAP and QT interval between two groups (all 0.05). There were no remarkable differences of the levels of serum histamine, ALT, AST, BUN, Cre, TT, PT, APTT and FIB before and after administration of neuromuscular blockade antagonists (neostigmine or Sugammadex) in the same group patients (all 0.05), also no significant differences between group C and group S at the same time points (all 0.05). Average time of tracheal tube extubation in group S [(3.7±1.3) min] was sharply shorter than that in group C [(14.5±4.4) min, 2.266, 0.05)]. There were no patients with allergy, skin itching, sensory abnormality in these two groups. There were no significant difference of the incidence of postoperative nausea and vomiting between these two groups. There were 5 patients with respiratory depression in group C and no respiratory depression patient in group S, the difference was statistically significant between these two groups (χ(2)=5.263, 0.05). Sugammadex is effective for antagonizing the neuromuscular blockade of rocuronium in patients with radical resection of lung cancer under thoracoscope, and can shorten the time of tracheal tube extubation after surgery.

摘要

探讨舒更葡糖钠拮抗胸腔镜下肺癌根治术患者神经肌肉阻滞的有效性及安全性。选取2019年3月至9月在郑州大学附属肿瘤医院行胸腔镜下肺癌根治术的100例患者,随机分为对照组(C组)和舒更葡糖钠组(S组)。所有患者均采用静脉靶控输注丙泊酚和瑞芬太尼进行麻醉诱导和维持,并间断静脉注射罗库溴铵进行神经肌肉阻滞。术中采用脑电双频指数(BIS)监测麻醉深度,采用四个成串刺激(TOF)评估神经肌肉阻滞。行单肺机械通气及双腔气管插管,术后实施患者自控镇痛。C组患者在关胸后给予新斯的明(2mg)联合阿托品(0.5 - 1.0mg),S组患者在关胸后TOF计数≥2时给予舒更葡糖钠(2mg/kg),然后根据拔管指征拔除双腔气管导管。在以下时间点:T(0)(麻醉诱导前即刻)、T(1)(气管插管前即刻)、T(2)(关胸后即刻)、T(3)(术后1h)、T(4)(术后6h)、T(5)(术后24h)、T(6)(术后48h),记录心率(HR)、平均动脉压(MAP),测量并计算QT间期(V3心电图),检测肝功能指标[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)]、肾功能指标[血尿素氮(BUN)、肌酐(Cre)]及凝血功能指标[凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)和纤维蛋白原(FIB)]。记录手术时长、术后48h内情况(气管导管拔除时间、呼吸抑制/功能障碍、过敏、恶心呕吐、皮肤瘙痒、感觉异常)、病理类型及术后住院时间。两组患者的年龄、性别比、体重指数(BMI)、美国麻醉医师协会(ASA)分级比例、手术时长、病理类型及术后住院时间、HR、MAP和QT间期比较,差异均无统计学意义(均P>0.05)。同组患者在给予神经肌肉阻滞拮抗剂(新斯的明或舒更葡糖钠)前后血清组胺、ALT、AST、BUN、Cre、TT、PT、APTT和FIB水平比较,差异均无统计学意义(均P>0.05),两组在同一时间点比较,差异亦无统计学意义(均P>0.05)。S组气管导管平均拔除时间为(3.7±1.3)min,明显短于C组的(14.5±4.4)min,差异有统计学意义(t = 2.266,P<0.05)。两组均无过敏、皮肤瘙痒、感觉异常患者。两组术后恶心呕吐发生率比较,差异无统计学意义。C组有5例患者发生呼吸抑制,S组无呼吸抑制患者,两组比较差异有统计学意义(χ² = 5.263,P<0.05)。舒更葡糖钠可有效拮抗胸腔镜下肺癌根治术患者罗库溴铵的神经肌肉阻滞,并可缩短术后气管导管拔除时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验